Viking Therapeutics says VK2809 study achieves primary, secondary endpoints
Viking Therapeutics announced the presentation of results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. As previously reported, the study successfully achieved both its primary and secondary endpoints, and demonstrated an encouraging safety and tolerability profile. Newly presented data provide further detail on the trial endpoints, highlighting the changes to LDL-C, atherogenic proteins, and other liver parameters. The results were presented Monday, November 12 as part of the Oral Late-Breaker session of The Liver Meeting 2018, the annual meeting of the American Association for the Study of Liver Diseases, held November 9-13 in San Francisco, CA.